title: [The selection of taxol resistance associated genes in ovarian cancer cell line by mRNA DD].
abstract: OBJECTIVE
  One of the main reasons of the treatment failure for ovarian cancer is the emergence of drug resistance in which several genes involved. The purpose of the study was to select the genes related to Taxol resistance in ovarian cancer.
  
  
  METHODS
  Resistant ovarian cancer cell line, Skov3/Taxol-25, was established by interval exposure Skov3 to Taxol. mRNA was compared between Skov3 and Skov3/Taxol-25 by mRNA DD.
  
  
  RESULTS
  Skov3/Taxol-25 showed 44 times increase resistance to Taxol after 12 months of induction. There were 22 new differential bands obtained from Skov3/Taxol-25 as compared with Skov3. 18 bands were special by repeated PCR. In the 5 sub-clones, three clones were homologous to the known gene. 105/106 base pair of clone 1 were homologous to tPA (tissue plasminogen activator), 261/268 of clone 3 to Kiaa 0372, and 406/409 of clone 18 to LDLC. The other 2 ESTs were new gene segments, which were banked to Genbank with the number of AF120327 and AF120328. The identification by RT-PCR revealed that both tPA and Kiaa0372 were special genes from Skov3/Taxol-25, while LDLC was pseudopositive.
  
  
  CONCLUSIONS
  Several genes were involved in the resistance to Taxol in ovarian cancer. The enhanced expression of tPA indicated the increased ability of metastasis after the acquisition of resistance to taxol.
authors.affiliation: Department of Obstetrics & Gynecology, Chinese PLA General Hospital, Beijing, 100853, China.
authors.forename: G
authors.initials: G
authors.lastname: Cheng
authors.forename: F
authors.initials: F
authors.lastname: Tian
authors.forename: Y
authors.initials: Y
authors.lastname: Li
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D020224:Expressed Sequence Tags; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008969:Molecular Sequence Data; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D017239:Paclitaxel / Q000494:pharmacology*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D010959:Tissue Plasminogen Activator / Q000235:genetics; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D012333:RNA, Messenger; D010959:Tissue Plasminogen Activator; D017239:Paclitaxel